Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Open access
Gabay, Cem, Fautrel, Bruno, Rech, Jürgen, Spertini, François, Feist, Eugen, Kötter, Ina, Hachulla, Eric, Morel, Jacques, Schaeverbeke, Thierry, Hamidou, Mohamed A, Martin, Thierry, Hellmich, Bernhard, Lamprecht, Peter, Schulze-Koops, Hendrik, Courvoisier, Delphine Sophie, Sleight, Andrew, Schiffrin, Eduardo Jorge·2018·Annals of the Rheumatic Diseases

Abstract

OBJECTIVES: Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD. METHODS: In this phase II, open-label study, patients were ≥18 years with active AOSD plus fever or C reactive protein (CRP) levels ≥10 mg/L despite treatment with prednisone and/or conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Previous biological DMARD treatment was permitted. Patients received tadekinig alfa 80 mg or 160 mg subcutaneously three times per week for 12 weeks; those receiving 80 mg not achieving early predicted response criteria (reduction of ≥50% CRP values from baseline and fever resolution) were up-titrated to 160 mg for a further 12 weeks. The primary endpoint was the occurrence of adverse events (AEs) throughout the study. RESULTS: Ten patients were assigned to receive 80 mg tadekinig alfa and 13 patients to the 160 mg dose. One hundred and fifty-five treatment-emerging AEs were recorded, and 47 were considered related to the study drug. Most AEs were mild and resolved after drug discontinuation. Three serious AEs occurred, one possibly related to treatment (toxic optic neuropathy). At week 3, 5 of 10 patients receiving 80 mg and 6 of 12 patients receiving 160 mg achieved the predefined response criteria. CONCLUSIONS: Our results indicate that tadekinig alfa appears to have a favourable safety profile and is associated with early signs of efficacy in patients with AOSD. TRIAL REGISTRATION NUMBER: NCT02398435.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2017-212608

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 291

Metadata

Authors
Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Kötter, I., Hachulla, E., Morel, J., Schaeverbeke, T., Hamidou, M. A., Martin, T., Hellmich, B., Lamprecht, P., Schulze-Koops, H., Courvoisier, D. S., Sleight, A., & Schiffrin, E. J.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2018-06
Volume
77
Issue
6
Pages
840-847
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2788608061
Cited by
291
References
17
FWCI
20.67
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. https://app.cochat.ai/papers/10.1136/annrheumdis-2017-212608
The paper
Gabay, C., Fautrel, B., Rech, J., Spertini, F., Feist, E., Kötter, I., Hachulla, E., Morel, J., Schaeverbeke, T., Hamidou, M. A., Martin, T., Hellmich, B., Lamprecht, P., Schulze-Koops, H., Courvoisier, D. S., Sleight, A., & Schiffrin, E. J. (2018). Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-212608

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.